In the past, most patients with multiple myeloma (MM) died within 5-10 years following diagnosis. Within the past decade, several new therapeutic interventions have been introduced, including autologous stem cell transplant, thalidomide, lenalidomide, and bortezomib. We estimated trends in age specific 5-and 10-year relative survival of MM 
Introduction
In the past, most patients with multiple myeloma (MM) died within 5-10 years following diagnosis. Several new therapeutic interventions have been introduced for MM over the past decade. These include autologous stem cell transplant (SCT) and novel agents including thalidomide, an anti-angiogenic and immunomodulatory small molecule, lenalidomide, a derivative of thalidomide, and bortezomib, a protosome inhibitor. All three novel agents have been shown to be active in MM, and regimens containing one of these compounds are gradually replacing chemotherapy-only regimens as standard of care in MM for patients who are not candidates for SCT 1, 2 . The impact of such therapeutic innovation and its dissemination on long-term prognosis should be monitored in an as timely as possible manner, but is only disclosed with substantial delay by conventional methods of survival analysis. We aimed to disclose trends from 1990-92 to 2002-04 and to derive up-to-date estimates of long-term survival of patients with MM by novel techniques of period survival analysis 3, 4 . Due to the differential application, efficacy and tolerance of novel therapies according to age, we were specifically interested in age specific trends of prognosis. For personal use only. on April 9, 2017 . by guest www.bloodjournal.org From cancer reporting system and for their epidemiologically significant population subgroups. The SEER population is comparable to the general United States population with regard to measures of poverty and education, though it tends to be more urban and has a higher proportion of foreign-born persons than the latter.
Methods

All data presented in this paper
For this analysis, we selected 27,038 patients aged 15 years or older with a first diagnosis of MM (and no previous cancer diagnosis) between 1980 and 2004, who have been followed for vital status until the end of 2004. After exclusion of 58 patients (0.21%) who were reported by autopsy only and 457 patients (1.69%) who were reported by death certificate only, there remained 26,523 patients (98.10%) for the survival analysis.
Five-and 10-year survival was calculated for the calendar periods 1990-1992, 1993-1995, 1996-1998, 1999-2001 and 2002-2004 using the period analysis methodology 3 . Furthermore, we tested for statistical significance of trends in 5-and 10-year year survival between 1990-1992 and 2002-2004 by a recently described modelling approach 4 . All analyses were carried out separately for the following 5 major age groups: <50, 50-59, 60-69, 70-79, and 80+.
With period analysis, first proposed by Brenner and Gefeller in 1996, 6 only survival experience during the period of interest is included in the analysis. This is achieved by left truncation of observations at the beginning of the period in addition to right censoring at its end. A graphical illustration of the data included to estimate 10-year relative survival for the 2002-04 period compared to the data used to derive the most up-to-date estimate of 10-year survival from the same database using traditional "cohort analysis" is shown in figure 1 . The latter would pertain to patients diagnosed in 1992-94 only and would thus not capture recent progress in therapy. It has been shown by extensive empirical evaluation that period analysis provides more up-to-date long term survival estimates than traditional "cohort-based" survival
For personal use only. on April 9, 2017. by guest www.bloodjournal.org From analysis, and quite closely predicts long-term survival expectations of cancer patients diagnosed within the period of interest 7, 8 .
In addition to 5-year survival from diagnosis, we calculated 5-year survival in the subsequent 5 years among patients who have already survived 1, 2, 3, 4, and 5 years since diagnosis. In this way, trends and recent achievements in late survival can be analyzed specifically. They are of particular interest for MM, given the frequency of late deaths among patients with this malignancy.
According to standard practice in population-based cancer survival analysis, relative rather than absolute survival was calculated. Relative survival reflects survival of cancer patients compared to survival of the general population. It is calculated as the ratio of absolute survival of cancer patients divided by the expected survival of a group of persons of the corresponding sex, age and race in the general population 9, 10 . Estimates of expected survival were derived according to the so-called Ederer II method 11 using US sex, age and race specific life tables 12 .
All analyses were performed with the SAS software package using previously described macros for period analysis 3, 4 . 
Results
Numbers
Discussion
This application of period analysis to age specific long-term survival of patients with MM discloses recent major improvements in younger age groups (below age 60) which were starting in the middle and late 1990s and are ongoing since then. Not only early deaths, but especially late deaths years after initial treatment are reduced in these age groups. This way, 10-year relative survival of approximately 40% and 30% was achieved in age groups <50 and 50-59 in 2002-2004. Improvements remained much more modest and mostly non-significant in older age groups, and no improvement at all was seen in patients above 80 years of age.
To the best of our knowledge, this is the first in-depth population-based analysis of long-term survival of MM patients by age using the period analysis methodology. The relative survival figures for the 2002-04 period disclosed by this approach are higher than previously available figures 13, 14 and this encouraging development should be disclosed to patients, clinicians, and researchers in an as timely as possible manner. Although the period estimates of long-term survival are more up-to-date than estimates obtained by traditional cohort analysis, even the period estimates may still be somewhat too pessimistic as they still partly reflect the survival experience of patients first diagnosed and treated in earlier years. Therefore, survival expectations of patients diagnosed in 2002-04 may even be somewhat higher. This may be particularly true for older patients who may benefit from treatment with novel agents, the earliest of which were introduced in the late 1990s, more than from SCT.
Prior to the late 1990s, treatment for MM consisted of chemotherapy with or without autologous SCT rescue. Patients not eligible for SCT were classically treated with vincristine, adriamycin, and dexamethasone (VAD) or melphalan and prednisone (MP) chemotherapy 1, 15 .
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Although chemotherapy with these drugs can produce responses in MM, cures are essentially unheard of and 5-year survival using chemotherapy alone is very poor.
High dose melphalan with or without total body irradiation followed by autologous SCT improves survival in patients with MM 16 . Prior to the early 1990s, SCT was limited to patients under 40 years of age. As improvements in SCT protocols decreased the risk of SCT, its use was expanded to more patients, with some patients as old as 75 being eligible under some current protocols 17 . and overall survival of greater than 12 months for patients treated with thalidomide 18 . Other studies of thalidomide in relapsed and refractory melanoma showed similar results 19, 20 . Later studies demonstrated that the addition of thalidomide to treatment protocols, both with and . Bortezomib, a proteosome inhibitor, was developed in the early 21 st century.
It was initially investigated in a number of malignancies and has been shown to be effective in Additionally, elderly patients are underrepresented in clinical trials, therefore, less is known about the natural history and response to treatment of MM in this population than in younger patients 28, 29 . There is some evidence that MM may be under-treated in the elderly, even after accounting for co-morbid conditions. One cohort study of patients aged 75+ showed that treatment was given to only 72% of patients and further chemotherapy was given to only 25%
For personal use only. on April 9, 2017. by guest www.bloodjournal.org From of patients on relapse 30 . SCT, which is still the therapy that offers patients with MM the best chance of long term survival, is offered to elderly patients only rarely. Additionally, the prothrombotic effects of thalidomide may have led clinicians to be reluctant to use it in older patients. However, recent studies of thalidomide and bortezomib in older patients suggest that they can be used safely and effectively in this population 31, 32 . The combination of thalidomide with MP produced 3-year survival rates of 80% in patients aged 60-85 in one study 31 .
Notably, cardiac disease, respiratory disease, and abnormal liver or kidney function were not exclusion criteria in this study, suggesting that the results may be applicable to a broad range of older adults with MM. Therefore, progress in the treatment of older patients with MM may be seen in the next few years, as treatment with newer agents plus chemotherapy becomes more common and clinicians become more comfortable using them in older patients. Further trials which include older patients with MM are still needed to delineate the best use of SCT, chemotherapy, and novel agents in this population.
In the interpretation of our results, a number of limitations requires careful consideration.
Because the SEER database does not contain information on chemotherapeutic or other medical treatment, nor on the location of treatment, the role of these factors cannot be assessed directly. Likewise, the SEER database does not contain stage information for myeloma which precludes assessment of a potential role of earlier diagnosis in improved survival. A major impact of earlier diagnosis seems unlikely though, given that no routine screening tests for MM have been introduced between the 1980s and the early 21 st century.
In summary, our population-based period analysis discloses significant, major progress in the survival of MM patients since the early1990s. Most likely, improvements in SCT and consequent extension of its use to older and less healthy patients account for the substantially improved survival in patients under 60 years of age during the 1990s and early 21 st century. Gondos critically reviewed and contributed to finalizing the paper.
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